Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone in Bipolar Depression or MDD with Mixed Features
NCT04285515Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Feb 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of lumateperone in bipolar I disorder, Bipolar II disorder (BP-II), major depressive disorder (MDD), sponsored by Intra-Cellular Therapies. Started Feb 2020; status: completed.
02
Drugs
lumateperone
03
Conditions
bipolar I disorderBipolar II disorder (BP-II)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04285515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04285515.